Evidence map›Paper›PMID 26136920›Full record

ArticleExperimental and therapeutic medicine2015

Recurrent pulmonary synovial sarcoma effectively treated with amrubicin: A case report.

Hiroaki Satoh, Norio Takayashiki, Toshihiro Shiozawa, Kunihiko Miyazaki, Gen Ohara, Katsunori Kagohashi, Koichi Kurishima, Shintaro Sugita, Tomoyuki Aoyama, Tadashi Hasegawa and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Synovial Sarcoma: Molecular Biology, Pathology, and Therapeutic Strategies.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hiroaki SatohDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 210-0015, Japan.
Norio TakayashikiDivision of Pathology, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 210-0015, Japan.
Toshihiro ShiozawaDivision of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
Kunihiko MiyazakiDivision of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
Gen OharaDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 210-0015, Japan.
Katsunori KagohashiDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 210-0015, Japan.
Koichi KurishimaDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 210-0015, Japan.
Shintaro SugitaDepartment of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan.
Tomoyuki AoyamaDepartment of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan.
Tadashi HasegawaDepartment of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan.
Nobuyuki HizawaDivision of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
University of Tsukuba · JPSapporo Medical University · JPNational Hospital Organization Mito Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary synovial sarcoma is a rare but aggressive disease. The present study describes the case of a 68-year-old female with pulmonary synovial sarcoma. The patient was mistakenly treated for small cell lung cancer due to false-positive staining for synaptophysin and cluster of differentiation 56. Despite severe myelotoxicity, platinum-containing chemotherapies (cisplatin plus irinotecan and carboplatin plus etoposide) were not effective. As a third-line therapy, the patient received amrubicin (AMR) monotherapy. A partial response was achieved, and the patient was able to undertake ordinary daily life at home for 13 months from the initiation of AMR chemotherapy. Due to the atypical clinical condition and unusual response to chemotherapy in this patient, the pathological examination was repeated. The SS18 split-signal was detected in fluorescence

Indexed as

amrubicinchemotherapypulmonary synovial sarcoma

Identifiers

PMID26136920
PMCPMC4471737
OpenAlexW2128897197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.